Pfizer为Cresemba的欧洲强劲销售增长向Basilea支付了30万加元。 Pfizer pays Basilea $30M for Cresemba's strong European sales growth.

由于其抗真菌药Cresemba (伊萨武可纳) 在欧洲的销售强,Basilea Pharmaceutica从Pfizer获得了3000万美元的里程碑性支付,该药在全球销售额同比增长了27%,到2025年6月全球销售额达到6.52亿美元. Basilea Pharmaceutica received a $30 million milestone payment from Pfizer due to strong European sales of its antifungal drug Cresemba (isavuconazole), which saw a 27% year-on-year sales increase to $652 million globally through June 2025. 该药物在70多个国家(包括美国和大多数欧盟国家)得到批准,治疗严重真菌感染,如1岁及以上病人的侵袭性大肠杆菌病和肌肉硬化病。 The drug, approved in over 70 countries including the U.S. and most EU nations, treats serious fungal infections like invasive aspergillosis and mucormycosis in patients aged one and older. 该药物以静脉注射和口服两种形式提供,并在多个区域具有无主药物地位。 It is available in both intravenous and oral forms and holds orphan drug status in multiple regions.